GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » Cyclically Adjusted PB Ratio

Fennec Pharmaceuticals (STU:RV41) Cyclically Adjusted PB Ratio : 12.00 (As of May. 28, 2024)


View and export this data going back to . Start your Free Trial

What is Fennec Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-28), Fennec Pharmaceuticals's current share price is €6.00. Fennec Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €0.50. Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 12.00.

The historical rank and industry rank for Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:RV41' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 9.21   Med: 16.78   Max: 23.75
Current: 12.46

During the past years, Fennec Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 23.75. The lowest was 9.21. And the median was 16.78.

STU:RV41's Cyclically Adjusted PB Ratio is ranked worse than
93.12% of 654 companies
in the Biotechnology industry
Industry Median: 1.73 vs STU:RV41: 12.46

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Fennec Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €0.102. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.50 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Fennec Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.76 20.21 9.33 19.78 21.59

Fennec Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.73 17.62 14.18 21.59 20.54

Competitive Comparison of Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Fennec Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=6.00/0.5
=12.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fennec Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Fennec Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.102/131.7762*131.7762
=0.102

Current CPI (Mar. 2024) = 131.7762.

Fennec Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 -0.348 100.560 -0.456
201409 -0.254 100.428 -0.333
201412 0.047 99.070 0.063
201503 0.072 99.621 0.095
201506 0.091 100.684 0.119
201509 0.083 100.392 0.109
201512 0.046 99.792 0.061
201603 0.020 100.470 0.026
201606 0.304 101.688 0.394
201609 0.276 101.861 0.357
201612 0.248 101.863 0.321
201703 0.196 102.862 0.251
201706 0.551 103.349 0.703
201709 0.469 104.136 0.593
201712 1.228 104.011 1.556
201803 1.126 105.290 1.409
201806 1.132 106.317 1.403
201809 1.025 106.507 1.268
201812 0.942 105.998 1.171
201903 0.854 107.251 1.049
201906 0.733 108.070 0.894
201909 0.685 108.329 0.833
201912 0.537 108.420 0.653
202003 0.385 108.902 0.466
202006 1.265 108.767 1.533
202009 1.026 109.815 1.231
202012 0.919 109.897 1.102
202103 0.805 111.754 0.949
202106 0.711 114.631 0.817
202109 0.621 115.734 0.707
202112 0.537 117.630 0.602
202203 0.437 121.301 0.475
202206 0.310 125.017 0.327
202209 0.108 125.227 0.114
202212 -0.092 125.222 -0.097
202303 -0.260 127.348 -0.269
202306 -0.339 128.729 -0.347
202309 -0.374 129.860 -0.380
202312 -0.394 129.419 -0.401
202403 0.102 131.776 0.102

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fennec Pharmaceuticals  (STU:RV41) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Fennec Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals (STU:RV41) Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals (STU:RV41) Headlines

No Headlines